Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser

Journal of Clinical Virology

Volumn 58, Issue 1, 2013, Pages 331-333

  Elsharkawy, Ahmed M ^a   Schwab, Ulrich ^b   McCarron, Brendan ^c   Burt, Alastair D ^d   Daly, Ann K ^d   Hudson, Mark ^d,e   Masson, Steven ^d,e  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Acute liver failure; CYP2B6; Drug induced liver injury; Efavirenz; HIV; Liver transplantation

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; RALTEGRAVIR;

ACUTE LIVER FAILURE; ADULT; ARTICLE; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LIPODYSTROPHY; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; PRIORITY JOURNAL; VIRUS LOAD;

EID: 84881506706     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.05.003     Document Type: Article

References (21)

1. Gazzard B.G., Anderson J., Babiker A., Boffito M., Brook G., Brough G., et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008, 9:563-608.
2. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother 2009, 64:910-928.
3. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245.
4. Marzolini C., Telenti A., Decosterd L.A., Greub G., Biollaz J., Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001, 15:71-75.
5. Habtewold A., Amogne W., Makonnen E., Yimer G., Riedel K.D., Ueda N., et al. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother 2011, 66:2350-2361.
6. Turkova A., Ball C., Gilmour-White S., Rela M., Mieli-Vergani G. A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation. J Antimicrob Chemother 2009, 63:623-625.
7. Saves M., Raffi F., Clevenbergh P., Marchou B., Waldner Combernoux A., Morlat P., et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in HIV-infected patients. Antimicrob Agents Chemother 2000, 44:3451-4345.
8. Den Brinker M., Wit F., Wertheim-van Dillen P., Jurriaans S., Weel J., Van Leeuwen R., et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000, 14:2895-2902.
9. van Leth F., Phanuphak P., Ruxrungtham K., Baraldi E., Miller S., Gazzard B., et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004, 363:1253-1263.
10. Bruck S., Witte S., Brust J., Schuster D., Mosthaf F., Procaccianti M., et al. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res 2008, 13:343-348.
11. Jao J., Sturdevant M., del Rio Martin J., Schiano T., Fiel M.I., Huprikar S. Nevirapine-induced stevens johnson-syndrome and fulminant hepatic failure requiring liver transplantation. Am J Transplant 2010, 10:1713-1716.
12. Bossi P., Colin D., Bricaire F., Caumes E. Hypersensitivity syndrome associated with efavirenz therapy. Clin Infect Dis 2000, 30:227-228.
13. Behrens G.M., Stoll M., Schmidt R.E. Pulmonary hypersensitivity reaction induced by efavirenz. Lancet 2001, 357:1503-1504.
14. Abrescia N., D'Abbraccio M., Figoni M., Busto A., Butrico E., De Marco M., et al. Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a treatment-naive female AIDS patient without hepatitis virus co-infection. J Antimicrob Chemother 2002, 50:763-765.
15. Daly A.K., Day C.P. Genetic association studies in drug-induced liver injury. Drug Metab Rev 2012, 44:116-126.
16. Haas D.W., Smeaton L.M., Shafer R.W., Robbins G.K., Morse G.D., Labbe L., et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an adult AIDS clinical trials group study. J Infect Dis 2005, 192:1931-1942.
17. Rotger M., Colombo S., Furrer H., Bleiber G., Buclin T., Lee B.L., et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005, 15:1-5.
18. Yimer G., Amogne W., Habtewold A., Makonnen E., Ueda N., Suda A., et al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J 2012, 12:499-506.
19. Kappelhoff B.S., van Leth F., Robinson P.A., MacGregor T.R., Baraldi E., Montella F., et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations?. Antivir Ther 2005, 10:489-498.
20. Nyakutira C., Roshammar D., Chigutsa E., Chonzi P., Ashton M., Nhachi C., et al. High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008, 64:357-365.
21. Maimbo M., Kiyotani K., Mushiroda T., Masimirembwa C., Nakamura Y. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. Eur J Clin Pharmacol 2012 Mar, 68:267-271.